1. Scrip
  2. >>Focus On Asia

GSK Launches Relvar For Asthma In Japan, First ICS/LABA Administered Once A Day

GlaxoSmithKline has launched Relvar and Ellipta (fluticasone furoate/vilanterol) for bronchial asthma in Japan.

GlaxoSmithKline launched Relvar and Ellipta (fluticasone furoate / vilanterol) for bronchial asthma in Japan, the company announced Dec. 9. The drug is the first ICS/LABA combination drug that is effective for 24 hours and is administered just once a day. The prices for the two products are ¥2,816.80 ($27.37) and ¥3,143.90 respectively, with sales expected to peak at ¥24 billion with 1.3 million patients. GSK launched Advair, a twice-a-day ICS/LABA combination in 2007, and sales of that product were at ¥50.3 billion in 2012. Approximately 8% of the Japanese population suffers from bronchial asthma. (Click Here For More – Japanese Language

)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics, Biosimilars

 
• By Dave Wallace

A free trade agreement between the UK and India could offer “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

 
• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.